Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Analysis: Citigroup Maintains Neutral Rating Amid Strong Financials

Font: Financial Modeling Prep  • May 06, 2026

• Citigroup maintains a "Neutral" rating but raises its price target for Establishment Labs Holdings Inc. (NASDAQ:ESTA) to $76, signaling a more positive outlook despite the unchanged rating.
• The medical technology company reported robust first-quarter revenue of $59.9 million, a 44.7% increase year-over-year, driven by strong Motiva sales and leading to raised full-year guidance.
• Establishment Labs Holdings Inc. demonstrated significant improvement in profitability, narrowing its quarterly loss to $0.40 per share and achieving a positive adjusted EBITDA of $1.2 million.

Establishment Labs Holdings Inc. (NASDAQ:ESTA) is a medical technology company that focuses on women's health and wellness, primarily known for its Motiva line of breast implants. The company operates globally and has a market capitalization of approximately $2.19 billion. It competes in the aesthetic and reconstructive surgery market.

On May 6, 2026, the investment bank Citigroup maintains its Neutral rating for Establishment Labs Holdings Inc. A Neutral rating, often called a "hold," suggests that investors should not buy or sell the stock at its current price. At the time of the update, the stock was trading at $74.94 per share.

Citigroup also raises its price target for Establishment Labs Holdings Inc. to $76 from a previous target of $65. A price target represents an analyst's estimate of a stock's future value. This upward revision indicates a more positive outlook on the company's ability to grow, even while the overall rating remains neutral.

This positive outlook is supported by strong financial results. As highlighted by Business Wire, Establishment Labs Holdings Inc. reports first-quarter revenue of $59.9 million, a 44.7% increase from the same period in 2025. This performance, which includes $19.6 million from Motiva sales in the U.S., leads the company to raise its full-year revenue guidance.

The company also shows signs of improving profitability. As noted by Zacks, its quarterly loss of $0.40 per share is a marked improvement from a $0.70 loss a year ago. Furthermore, Establishment Labs Holdings Inc. reports an adjusted EBITDA income of $1.2 million, a significant turnaround from a loss of $12.1 million in the first quarter of 2025.